A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial

OBJECTIVES: Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the Januse-Kinase signalling transducer and activator of transcription (JAK-STAT) pathway. Moreover, it reduces the receptor mediated viral endo...

Descripción completa

Detalles Bibliográficos
Autores principales: Moreno-González, G., Mussetti, A., Albasanz-Puig, A., Salvador, I., Sureda, A., Gudiol, C., Salazar, R., Marin, M., Garcia, M., Navarro, V., de la Haba Vaca, I., Coma, E., Sanz-Linares, G., Dura, X., Fontanals, S., Serrano, G., Cruz, C., Mañez, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862837/
https://www.ncbi.nlm.nih.gov/pubmed/33546739
http://dx.doi.org/10.1186/s13063-021-05072-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862837/
https://www.ncbi.nlm.nih.gov/pubmed/33546739
http://dx.doi.org/10.1186/s13063-021-05072-4

Ejemplares similares